2/2014 vol. 21
Get citation
REVIEW PAPER
Hypertensive nephropathy – A yet unsolved problem
,
 
,
 
,
 
 
 
 
More details
Hide details
1
Department of Internal Medicine, Gastroenterology and Hepatology, University of Warmia and Mazury in Olsztyn, Poland
 
2
Family Medicine Unit, Department of Medical Sciences, University of Warmia and Mazury in Olsztyn, Poland
 
 
Submission date: 2014-02-26
 
 
Acceptance date: 2014-08-27
 
 
Online publication date: 2014-09-26
 
 
Publication date: 2020-04-06
 
 
Corresponding author
Monika Kubiak   

Department of Internal Medicine, Gastroenterology, Cardiology and Infectiology, Clinical University Hospital in Olsztyn, Warszawska 30, 10-082 Olsztyn, Poland. Tel.: +48 608 730 819.
 
 
Pol. Ann. Med. 2014;21(2):147–151
DOI: https://doi.org/10.1016/j.poamed.2014.08.002
 
 
Article (PDF)
References (43)
 
KEYWORDS
arterial hypertension
hypertensive nephropathy
MYH9
APOL1 genes
 
ABSTRACT
Introduction:
Despite increasingly more effective treatment methods of arterial hypertension (AH), there is a constant increase in the diagnosis of hypertensive nephropathy (HN). Diagnostic criteria of HN are not precisely defined.

Aim:
The aim of this paper is to present literature reports and systematize current knowledge on HN.

Discussion:
Although HN is defined as histological lesions in renal arteries, arterioles and interstitium that occur due to long-term primary AH, rarely diagnosis of HN is made on the basis of renal biopsy. Nephrologists agree that high blood pressure values exacerbate all forms of chronic kidney disease (CKD), accelerating its progression to end stage renal disease. However, there is no evidence that mild and moderate AH may initiate kidney damage. Recent years' discoveries of MYH9 and APOL1 gene polymorphism association with HN seem to confirm these doubts and prove that, at least in the African American population, HN may be a genetically determined disease.

Conclusions:
The concept of primary AH being the cause of HN requires reconsideration. There is evidence suggesting that lesions considered as secondary to AH may indeed be a genetically determined disorder.

CONFLICT OF INTEREST
None declared.
 
REFERENCES (43)
1.
Meyrier A, Simon P. Nephrosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant. 1996;11(11):2116–2120.
Google Scholar
 
 
2.
Fahr T. Über Nephrosklerose. Virchows Arch (Pathol Anat). 1919;226(2):119–178. http://dx.doi.org/10.1007/BF02....
CrossRef
 
Google Scholar
 
 
3.
Meyrier A. Hypertensive nephrosclerosis. Pathogenesis, diagnosis, management. Saudi J Kidney Dis Transpl. 1999;10(3):267–274.
Google Scholar
 
 
4.
Zucchelli P, Zuccala A. The diagnostic dilemma of hypertensive nephrosclerosis: the nephrologist's view. Am J Kidney Dis. 1993;21(5 Suppl. 2):87–91.
Google Scholar
 
 
5.
Perneger TV, Whelton PK, Klag MJ, Rossiter KA. Diagnosis of hypertensive end-stage renal disease: effect of patient's race. Am J Epidemiol. 1995;141(1):10–15.
Google Scholar
 
 
6.
Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR. Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrol Dial Transplant. 2000;15(11):1801–1810.
Google Scholar
 
 
7.
Tylicki L, Rutkowski B. Tubulointerstitial injury: early or late event in pathogenesis of hypertensive nephropathy? Kidney Int. 2004;65(5):1971–1972. author reply 1972.
Google Scholar
 
 
8.
Mai M, Geiger H, Hilgers KF, et al. Early interstitial changes in hypertension-induced renal injury. Hypertension. 1993;22(5):754–765.
Google Scholar
 
 
9.
Johnson RJ, Herrera-Acosta J, Schreiner GF, Rodriquez-Iturbe B. Subtle acquired injury as a mechanism of salt-sensitive hypertension. N Engl J Med. 2002;346(12):913–923.
Google Scholar
 
 
10.
Więcek A, Januszewicz A, Szczepańska-Sadowska E, eds. In: Hypertensiology: pathogenesis, diagnosis and treatment of arterial. Kraków: Medycyna Praktyczna; 2011.
Google Scholar
 
 
11.
Dasgupta I, Porter C, Innes A, Burden R. ‘‘Benign’’ hypertensive nephrosclerosis. QJM. 2007;100(2):113–119.
Google Scholar
 
 
12.
Marcantoni C, Fogo AB. A perspective on arterionephrosclerosis: from pathology to potential pathogenesis. J Nephrol. 2007;20(5):518–524.
Google Scholar
 
 
13.
Ojea Diez B, Marin R, Coto E, et al. [Clinical and genetic bases of hypertensive nephrosclerosis. Nefrosen Study]. Rev Nefrol. 2010;30(6):687–697 [in Spanish].
Google Scholar
 
 
14.
Manitius J. Hypertensive nephropathy – some concepts and controversies. Postępy Nauk Med. 2004;4:32–34 [in Polish].
Google Scholar
 
 
15.
Freedman BI, Sedor JR. Hypertension-associated kidney disease: perhaps no more. J Am Soc Nephrol. 2008;19(11):2047–2050.
Google Scholar
 
 
16.
Zucchelli P, Zuccala A. Recent data on hypertension and progressive renal disease. J Hum Hypertens. 1996;10(10):679–682.
Google Scholar
 
 
17.
Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end stage renal disease due to hypertension. Am J Kidney Dis. 1994;23(5):655–660.
Google Scholar
 
 
18.
Freedman BI, Iskander SS, Buckalev VM, Burkart JM, Appel RG. Renal biopsy findings in presumed hypertensive nephrosclerosis. Am J Nephrol. 1994;14(2):90–92.
Google Scholar
 
 
19.
Marin R, Gorostidi M, Diez-Ojea B. Nephrosclerosis. The Cinderella of chronic kidney disease. Nefrologia. 2010;30(3):275–279.
Google Scholar
 
 
20.
2013 ESH/ESC. Guidelines for the management of arterial hypertension.
Google Scholar
 
 
21.
Raine AE. Hypertension and the kidney. Br Med Bull. 1994;50(2):322–341.
Google Scholar
 
 
22.
Perera G. Hypertensive vascular disease: description and natural history. J Chronic Dis. 1955;1(1):33–34.
Google Scholar
 
 
23.
Hsu CY. Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials. J Hum Hypertens. 2001;15(2):99–106.
Google Scholar
 
 
24.
Madhavan S, Stockwell D, Cohen H, Alderman MH. Renal function during hypertensive treatment. Lancet. 1995;345(8952):749–751.
Google Scholar
 
 
25.
Toto RD. Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int Suppl. 2004;92:S102–S104.
Google Scholar
 
 
26.
Murea M, Freedman IB. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens. 2010;19(3):235–241.
Google Scholar
 
 
27.
Feld LG, Van Liew JB, Brentjens JR, Boylan JW. Renal lesions and proteinuria in the spontaneously hypertensive rat made normotensive by treatment. Kidney Int. 1981;20(5):606–614.
Google Scholar
 
 
28.
Johnson RJ, Alpers CE, Yoshimura A, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension. 1992;19(5):464–474.
Google Scholar
 
 
29.
Kim HS, Krege JH, Kluckman KD, et al. Genetic control of blood pressure and the angoiotensynogen locus. Proc Natl Acad Sci U S A. 1995;92(7):2735–2739.
Google Scholar
 
 
30.
Luke RG. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end-stage renal disease. Nephrol Dial Transplant. 1999;14(10):2271–2280.
Google Scholar
 
 
31.
Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondibetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185–1190.
Google Scholar
 
 
32.
Kopp JB, Smith MW, Nelson GW, et al. MYH9 is major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40(10):1175–1180.
Google Scholar
 
 
33.
Freedman BI, Murea M. Target organ damage in Africa American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14(1):21–28.
Google Scholar
 
 
34.
Genovese G, Friedmann DJ, Ross MD, et al. Association of trypanolytic Apol1 variants with kidney disease in African Americans. Science. 2010;329(5993):841–845.
Google Scholar
 
 
35.
Kronenberg F. APOL1 variants and kidney disease. There is no such thing as a free lunch. Nephrol Dial Transplant. 2011;26(3):775–778.
Google Scholar
 
 
36.
Marcantoni C, Ma LJ, Federspiel C, Fogo AB. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002;62(1):172–180.
Google Scholar
 
 
37.
Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int Suppl. 1992;36:33–37.
Google Scholar
 
 
38.
Pattaro C, Aulchenko YS, Isaacs A, et al. Genome-wide linkage analysis of serum creatinine in three isolated European populations. Kidney Int. 2009;76(3):297–306.
Google Scholar
 
 
39.
O'Seaghdha CM, Parekh RS, Hwang SJ, et al. The MYH9/ APOL1 region and chronic kidney disease in European- Americans. Hum Mol Genet. 2011;20(12):2450–2460.
Google Scholar
 
 
40.
Tavira B, Coto E, Tranche S, et al. Association between a MYH9 polymorphism (rs3752462) and renal function in the Spanish RENASTUR cohort. Gene. 2013;520(1):73–76.
Google Scholar
 
 
41.
McKnight AJ, Duffy S, Fogarty SD, Maxwell AP. Association of MYH9/APOL1 with chronic kidney disease in UK population. Nephrol Dial Transplant. 2012;27(9):3660–3670.
Google Scholar
 
 
42.
Allen CE, Sanders PW. Hypertensive nephrosclerosis: not enough of good thing? Am J Physiol Renal Physiol. 2013;304(6):674–675.
Google Scholar
 
 
43.
Chang J, Ma JZ, Zeng Q. Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in African American Study of Kidney Disease (AASK). Am J Physiol Renal Physiol. 2013;304(4):348–355.
Google Scholar
 
 
Share
Send by email
Indexes
 
Keywords index
Topics index
Authors index
© 2006-2023 Journal hosting platform by Bentus